Autosomal dominant CTLA‐4 haploinsufficiency with autoimmune infiltration
Rare genetic disorder of immune regulation from CTLA-4 haploinsufficiency.
CHAI disease, also known as autosomal dominant CTLA-4 haploinsufficiency with autoimmune infiltration, is a rare immune system disorder that highlights how the CTLA-4 protein controls cell signaling. It arises from heterozygous mutations in the CTLA4 gene, which provides the instructions for making cytotoxic T-lymphocyte antigen 4. This protein acts as an immune checkpoint receptor, found mainly on activated T cells and regulatory T cells, and is essential for maintaining peripheral immune tolerance by dampening immune responses after T cells are activated.
Because the mutations cause haploinsufficiency—meaning a single working copy of the gene cannot sustain normal immune regulation—the body loses proper immune control, paving the way for autoimmune disease. Research shows that this shortage of CTLA-4 reduces the suppressive ability of regulatory T cells while boosting the activity of effector T cells, worsening immune dysregulation.
**Presentation** The condition presents with a varied mix of immune and autoimmune complications. Reported issues include enteropathy, low levels of antibodies (hypogammaglobulinemia), frequent respiratory infections, granulomatous lymphocytic interstitial lung disease, and lymphocytic infiltration of non-lymphoid organs such as the intestine, lungs, brain, bone marrow, and kidneys. Patients may also develop autoimmune problems like thrombocytopenia, neutropenia, autoimmune hemolytic anemia, and swollen lymph nodes (lymphadenopathy). These symptoms reflect widespread immune dysfunction and ongoing inflammation.
**Related disorders** CHAI is closely related to LATAIE, a disorder caused by mutations in LRBA, a protein that helps transport and stabilize CTLA-4. Both conditions underscore the importance of CTLA-4 pathways in immune regulation, as LATAIE also involves immune checkpoint dysregulation.
**Mechanism** CTLA-4 normally acts as a brake on T cell activation. It competes with the stimulatory receptor CD28 for binding to CD80 and CD86 on antigen-presenting cells. When CTLA-4 binds these ligands, it suppresses immune responses by stopping T cell proliferation, which is crucial for preventing excessive immune attacks. Additionally, CTLA-4 can physically remove CD80 and CD86 from antigen-presenting cells through trans-endocytosis, further limiting co-stimulatory signals. In CHAI, mutations reduce CTLA-4 expression or f
- field
- Immunology, Genetics
- known_for
- Rare genetic disorder causing immune dysregulation due to CTLA-4 haploinsufficiency
- inheritance
- Autosomal dominant
- causative_gene
- CTLA4
- related_disorder
- LATAIE (LRBA deficiency)
Lore & Background
CHAI disease is characterized by a variable combination of immune and autoimmune complications, including enteropathy, hypogammaglobulinemia, recurrent respiratory infections, granulomatous lymphocytic interstitial lung disease, and lymphocytic infiltration of non-lymphoid organs such as the intestine, lung, brain, bone marrow, and kidney. Patients may also develop autoimmune disorders such as thrombocytopenia, neutropenia, autoimmune hemolytic anemia, and lymphadenopathy. These symptoms reflect widespread immune dysfunction and chronic inflammation.
The mechanism involves CTLA-4, a negative regulator of T cell activation that competes with the stimulatory receptor CD28 for binding to ligands CD80 and CD86 on antigen-presenting cells. CTLA-4 can also remove these ligands via trans-endocytosis. In CHAI, mutations reduce CTLA-4 expression or function, leading to unchecked T cell activation, immune dysregulation, and autoimmune attack on self-tissues.
Diagnosis typically involves genetic testing to identify pathogenic variants in the CTLA4 gene, along with immune profiling showing decreased CTLA-4 expression and abnormal T cell function. Clinical presentation varies widely, even among patients with the same mutation. Treatment strategies include immunosuppressive agents such as Rituximab and Abatacept, a fusion protein that mimics CTLA-4 function. Hematopoietic stem cell transplantation has also been explored as a potential treatment.
Reader's Guide
CHAI disease is significant as a model disorder for understanding the role of CTLA-4 in immune regulation and autoimmunity. It demonstrates how haploinsufficiency of a single immune checkpoint receptor can lead to widespread immune dysregulation, chronic inflammation, and multi-organ autoimmune damage. The condition is closely linked to LATAIE, another disorder involving CTLA-4 pathway dysfunction, highlighting the critical importance of CTLA-4 in maintaining immune homeostasis. The development of targeted therapies such as Abatacept, which mimics CTLA-4 function, illustrates how understanding the molecular mechanism of a rare disease can lead to rational treatment approaches. The variability in clinical presentation underscores the complexity of immune regulation and the need for early diagnosis to prevent progressive organ damage. As a very rare and likely underdiagnosed condition, CHAI also emphasizes the challenges in recognizing primary immunodeficiency disorders that overlap with more common autoimmune diseases.
Did You Know?
- CHAI disease is caused by heterozygous mutations in the CTLA4 gene, resulting in haploinsufficiency of the CTLA-4 protein.
- CTLA-4 can actively remove CD80 and CD86 from antigen-presenting cells via a process called trans-endocytosis.
- Abatacept, a treatment for CHAI, is a fusion protein that mimics the function of CTLA-4 by binding CD80 and CD86.
- CHAI is closely linked to LATAIE, a disorder caused by mutations in LRBA, a protein involved in CTLA-4 trafficking and stability.
More in Genetic diseases and disorders 1-24
Spotted an error? Know more?
This is a living reference — every entry is fact-audited, and reader corrections feed straight into our audit queue. Suggest an edit · See this site's audit record